Dermal pharmaceutical preparations |
| OF THE INVENTION The support which can be used in the present invention functions to retain a ... |
|
Substituted iminodiacids, their preparation and pharmaceutical compositions containing them |
| We claim: 1. A compound selected from the group consisting of iminodiacid compounds having the ... |
|
N-Acyl hexahydroindole-2-carboxylic acids and anti-hypertensive use thereof |
| We claim: 1. A compound of the formula I, ##STR24## in which n denotes 0 to 1, R denotes hydrogen, (... |
|
Substituted N-carboxymethyl-aminoacylaminoalkanoic acids useful as antihypertensive agents |
| OF THE INVENTION AND PREFERRED EMBODIMENTS In its broadest aspect, the present invention relates ... |
|
Racemates of optically active bicyclic imino-alpha-carboxylic esters |
| We claim: 1. A diasteromic salt of i. a bicyclic imino-.alpha.-carboxylic ester of the formulae Ia ... |
|
Disubstituted proline derivatives |
| We claim: 1. A compound of the formula I ##STR15## in which R.sup.1 and R.sup.2 together represent ... |
|
Carboxyalkyl dipeptides and anti-hypertensive use thereof |
| We claim: 1. A compound represented by the formula ##STR12## and the pharmaceutically acceptable ... |
|
|
Treatment of bone disorders with adrenomedullin
| Details |
Inventors: Coy, David H.; Cornish, Jillian; Reid, Ian Reginald; Cooper, Garth James Smith;
Assignee: Auckland UniServices Limited (Auckland, NZ); The Administrators of The Tulane Educational Fund (New Orleans, LA)
Primary Examiner: Hutzell; Paula K.
Assistant Examiner: Masood; Khalid
Attorney, Agent or Firm: Fish & Richardson P.C.
A method for promoting bone growth in a patient (e.g., a mammal such as a human) said method including the step of administering a therapeutically effective amount of adrenomedullin or an adrenomedullin agonist to said patient. |
|
DETAILED DESCRIPTION OF THE INVENTION It is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference. ADRENOMEDULLIN AND ADRENOMEDULLIN AGONISTS Adrenomedullin is a 52-amino acid having an amidated C-terminus. Many analogs, e. g. , carboxy terminal fragments, have been prepared, such as adrenomedullin(15-52)(SEQ ID NO:6), adrenomedullin(1-50)(SEQ ID NO:7), adrenomedullin(11-50)(SEQ ID NO:8), adrenomedullin(22-52)(SEQ ID NO:9), adrenomedullin(40-52)(SEQ ID NO:10), adrenomedullin(13-52)(SEQ ID NO:11), adrenomedullin(47-52)(SEQ ID NO:12), and adrenomedullin(45-52)(SEQ ID NO:13). See European Patent No. 622,458 A2; Lin, et al. , Eur. J. Pharmacol. 260:1-4 (1990); and Santiago, J. A. , et al. , Eur. J. of Pharmacology 272:115-118 (1995). What is meant by an adrenomedullin agonist is a compound which (1) has a high affinity (e. g. , a Ki of less than 1 . mu. M) for the adrenomedullin receptor (as defined by the receptor binding assay described in Owji, et al. , Endocrinology 136(5):2128 (1995)) and (2) promotes the proliferation of osteoblast cells (as defined below in the osteoblast proliferation assays). SYNTHESIS The synthesis of short amino acid sequences is well established in the peptide art. See, e. g. , Stewart, et al. , Solid Phase Peptide Synthesis (2d ed. , 1984). The following is the synthesis of adrenomedullin (27-52)(SEQ ID NO:1). Other such adrenomedullin agonists can be prepared by making appropriate modifications, within the ability of someone of ordinary skill in the filed of the synthetic method described herein
|
| Related patents |
|
|
99MTC(III) myocardial imaging agents and method of use
OF THE INVENTION The technetium compounds of the present invention which have been found most useful as myocardial imaging agents in humans comprise hexadentate ...
|
|
|
1,4-dihydro-4-oxo-3-quinoline derivatives as selectively toxic mammalian antibacterial agents
OF THE INVENTION Compounds of the formula I may be prepared as illustrated in the following reaction scheme. ##STR6## Referring to the above reaction scheme, compounds ...
|
|
|
Vaginal sponge delivery system
These and other objects of the invention are achieved in a product which broadly comprises (a) a sealed, air-tight package, enclosing therein (b) a sponge impregnated ...
|
|
|
Controlled release formulation
What is claimed is: 1. In a controlled release angiotensin converting enzyme inhibitor formulation in the form of an uncoated tablet from which upon ingestion ...
|
|
|
Formulations providing three distinct releases
We claim: 1. A therapeutic composition for oral administration consisting essentially of a pharmaceutical gelatin capsule containing film coated spheroids, which ...
|
|
|
Floating sustained release therapeutic compositions
OF THE INVENTION According to the present invention, therapeutic dosage forms have now been discovered which are easy to prepare, provide sustained release of contained ...
|
|
|
Solid oral dosage forms of ifosfamide
OF PREFERRED EMBODIMENTS The invention is illustrated by the following examples: EXAMPLE 1 Ifosfamide capsule mass In accordance with the invention, the capsule mass is ...
|
|
|
[(benzodioxan, benzofuran or benzopyran) alkylamino] alkyl substituted guanidines
We claim: 1. A compound of the formula: ##STR259## a pharmaceutically acceptable acid addition salt thereof, or a stereochemically isomeric form thereof, wherein: X is O,...
|
|
|
Methods for treating dermatitis using descarboethoxyloratadine
OF THE INVENTION The present invention encompasses a method of treating allergic asthma in a human while avoiding the concomitant liability of adverse side-effects ...
|
|
|
Fat emulsions containing isocarbacyclin
What is claimed is: 1. A pharmaceutical prostaglandin emulsion comprising: a mixture of vegetable oil, phospholipid, water, and a pharmaceutically effective amount of at ...
|
|
|